Physician profile
Lyndsey Rachelle Decesare
NPI 1912540543
$2,292.61
in general payments reported to CMS, 2019-2025
23 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $72.95 · 2023: $490 · 2024: $613 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $317.55 | 2023-2025 | Rexulti, Jynarque, Abilify Maintena |
| Astrazeneca Pharmaceuticals Lp | $284.22 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $274.30 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $162.91 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $154.08 | 2023-2024 | Edarbyclor, Edarbyclor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.35 | 2022-2025 | Xifaxan |
| Pfizer INC. | $120.56 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.98 | 2024-2025 | Jardiance, Ofev |
| Amgen INC. | $93.82 | 2022-2025 | Prolia, Evenity, Repatha |
| Exact Sciences Corporation | $91.99 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $88.03 | 2023-2025 | |
| Corcept Therapeutics | $80.77 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.30 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $52.22 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $45.64 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $44.35 | 2023-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $33.94 | 2022-2023 | |
| Lilly USA, LLC | $33.39 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $23.35 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $22.90 | 2025 | Onpattro |
| Astellas Pharma US INC | $22.83 | 2023 | Myrbetriq |
| Dexcom, INC. | $21.69 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $21.44 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyndsey Decesare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.